AquaBounty Technologies, Inc. (NASDAQ:AQB) Sees Significant Increase in Short Interest

AquaBounty Technologies, Inc. (NASDAQ:AQB) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totalling 423,300 shares, an increase of 452.6% from the December 15th total of 76,600 shares. Based on an average daily volume of 425,500 shares, the short-interest ratio is presently 1.0 days. Currently, 11.7% of the company’s stock are short sold.

AquaBounty Technologies Stock Down 4.7 %

AquaBounty Technologies stock traded down $0.04 during mid-day trading on Monday, hitting $0.74. The company had a trading volume of 121,412 shares, compared to its average volume of 439,162. The company has a quick ratio of 2.98, a current ratio of 3.02 and a debt-to-equity ratio of 0.05. AquaBounty Technologies has a 1 year low of $0.47 and a 1 year high of $2.79. The business has a fifty day moving average of $0.85 and a 200 day moving average of $1.14. The stock has a market cap of $2.84 million, a price-to-earnings ratio of -0.04 and a beta of 1.17.

AquaBounty Technologies (NASDAQ:AQB) last posted its earnings results on Tuesday, November 5th. The company reported ($0.88) EPS for the quarter, meeting analysts’ consensus estimates of ($0.88). AquaBounty Technologies had a negative net margin of 5,842.69% and a negative return on equity of 18.20%. The firm had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.10 million. During the same period last year, the firm posted ($1.60) EPS. On average, sell-side analysts expect that AquaBounty Technologies will post -4.86 earnings per share for the current fiscal year.

AquaBounty Technologies Company Profile

AquaBounty Technologies, Inc, a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts.